Daiichi Sankyo Reaffirms EUR 1 Billion Bavaria Investment Despite Uncertain Macro Environment

The Quick Take

• Japanese pharma giant Daiichi Sankyo reaffirmed commitment to invest more than EUR 1 billion in its Bavarian manufacturing operations
• The investment in Pfaffenhofen signals continued confidence in Germany as a pharma manufacturing hub amid global supply chain shifts
• Daiichi Sankyo co-developed blockbuster ADC drug Enhertu with AstraZeneca — Bavaria expansion supports this growing pipeline

Daiichi Sankyo, the Japanese pharmaceutical group that has become globally prominent through its partnership with AstraZeneca on the blockbuster antibody-drug conjugate Enhertu, has reaffirmed its plan to invest more than one billion euros in its Bavarian manufacturing facilities centered on Pfaffenhofen. The reaffirmation is significant because it comes against a backdrop of global pharma companies reassessing European capex amid regulatory and pricing pressures. Bavaria's life sciences ecosystem and Germany's skilled manufacturing workforce appear to remain compelling for Daiichi Sankyo's ADC production capacity build-out.

The EUR 1 billion investment reaffirmation has multiple market implications. For Daiichi Sankyo's equity, it demonstrates management confidence in the long-term trajectory of its ADC pipeline — Enhertu is expected to become one of the highest-selling oncology drugs of the decade. For AstraZeneca, the manufacturing expansion news is indirectly positive, as Daiichi Sankyo supplies Enhertu under their co-development agreement. The investment also reinforces Germany's attractiveness as a manufacturing jurisdiction at a time when U.S. tariff threats have added uncertainty to global supply chains.

Watch for Daiichi Sankyo's next earnings release for updated capex guidance confirming the Bavaria investment is on schedule. The broader ADC market is in a high-growth phase — Pfizer's Seagen acquisition and multiple late-stage ADC pipeline entrants indicate that manufacturing capacity is becoming a strategic differentiator. Any announcement of additional Daiichi Sankyo partnerships or licensing agreements beyond AstraZeneca would validate the expansion investment thesis. European pharma sector ETFs would benefit from positive sentiment around continued Japanese FDI into German life sciences.

Synthesized from 2 sources.